Navigation Links
Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
Date:12/6/2011

ALISO VIEJO, Calif., Dec. 6, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will report financial results for the quarter and year ended September 30, 2011 after market close on Monday, December 12, 2011. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.

Conference Call Information:
Domestic callers: 1-877-558-3407
International callers: +1-706-679-1941
Passcode: 33791527

Webcast information: Visit http://www.avanir.com.

A webcast replay will be available on the Avanir Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-855 859-2056 for domestic callers, or +1-404 537-3406 for international callers, and entering reservation code 33791527.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a registered trademark owned by Avanir Pharmaceuticals, Inc.

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
2. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
3. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
4. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
5. Avanir Pharmaceuticals to Participate in Two Investor Conferences
6. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
7. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
8. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
9. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
10. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
11. Avanir Pharmaceuticals Provides Update on European Regulatory Filing for NUEDEXTA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 ... that positive Phase 1 clinical data for Nektar,s lead ... (RCC) were presented at ASCO GU 2017.  NKTR-214 is ... T cells and Natural Killer (NK) cell abundance directly ... on these immune cells.  The results were presented by ...
(Date:2/17/2017)... 17, 2017 Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, ... global ablation technologies market is expected to grow at a CAGR ... market is expected to grow at a CAGR of 9.5% from ... and $9.05bn in 2026. ... How this report will benefit you Read on to ...
(Date:2/17/2017)... Feb. 17, 2017 Theravance Biopharma, Inc. ... the "Company") today announced the presentation of positive ... orally administered pan-Janus kinase (JAK) inhibitor designed to ... Congress of the European Crohn,s and Colitis Organization ... further data from its completed Phase 1 study ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the ... in large part by the Hospital Readmission Reduction Program (HRRP), the return of a ... area for hospitals across the nation. While many providers are struggling to leverage limited ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... over 10 years of research, development and clinical trials, the founder of Chigurupati ... a patented compound of FDA approved ingredients that when infused into alcohol, protect ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is ... ACE.P (pediatrics) is being created with the support of the Hearst Foundations. An initiative ... ACE.P will address what has been identified as a critical gap in preparing the ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection ... patient care, NWH has achieved Magnet® recognition for the second time, ... 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet ...
Breaking Medicine News(10 mins):